Document is current
Any future updates will be listed below
-
Authors
Rakhshandehroo, Taha
Mantri, Shreya R. https://orcid.org/0000-0002-1234-6856
Moravej, Heydar https://orcid.org/0009-0008-4197-9338
Louis, Benjamin B. V.
Salehi Farid, Ali
Munaretto, Leila
Regan, Kathryn
Khan, Radia M. M.
Wolff, Alexandra
Farkash, Zoe
Cong, Min
Kuhnast, Adrien
Nili, Ali https://orcid.org/0000-0002-1286-1858
Lee, Uk-Jae https://orcid.org/0000-0002-2352-6393
Allen, Harris H. https://orcid.org/0009-0001-4800-4700
Berland, Lea
Simkova, Ester https://orcid.org/0000-0002-6315-5857
Uslu, Safak C. https://orcid.org/0000-0003-4272-9492
Tavakolpour, Soheil
Rowley, Jennifer E.
Codet, Elisabeth
Shahbazian, Haneyeh
Baral, Jessika
Pyrdol, Jason
Jacobson, Caron A.
Nadeem, Omar
Nia, Hadi T. https://orcid.org/0000-0003-1970-9901
Wucherpfennig, Kai W. https://orcid.org/0000-0002-1829-302X
Rashidian, Mohammad
-
Funding
Funding for this research was provided by:
Dana-Farber Cancer Institute (Dana-Farber Cancer Institute Innovation Research Fund)
Harvard Medical School (Blavatnik Therapeutics Challenge Award)
- License Information
-
More Information
Article History
Received: 14 July 2023
Accepted: 27 June 2024
First Online: 30 July 2024
Competing interests
: T.R. and M.R. are inventors on a related patent application. M.R. is the scientific founder of Koi Biotherapeutics. C.A.J. serves as a consultant for Kite/Gilead, Novartis, BMS, Sana, Synthekine, Janssen, Miltenyi, Caribou, Galapagos, ADC Therapeutics, AstraZeneca and Abbvie, and receives research funding from Kite/Gilead. O.N. receives research support from Takeda and Janssen, participates on advisory boards for Bristol Myers Squibb, Janssen, Sanofi, Takeda and GPCR Therapeutics, and receives honoraria from Pfizer. The other authors declare no competing interests.
